Matching Articles
Back to the Disease Index
Allergy: Atopic Dermatitis
Results 1 to 3 of 3 articles.
In Brief: Elidel and Protopic
The Medical Letter on Drugs and Therapeutics • Mar 28, 2005 (Issue 1205)
The FDA issued a public health advisory on March 10, 2005 warning about a risk of cancer with topical formulations of tacrolimus (Protopic) and pimecrolimus (Elidel) used to treat eczema in adults and children more than 2 years old. Elidel has been heavily promoted to the general public on television. The warning was based on reports of dose-related cancer in animals and 29 reports of cancer (including 8 skin malignancies and 12 lymphomas) in adults and children treated with these immunosuppressive drugs. Cause and effect have not been established. When Protopic was first marketed, The...
http://secure.medicalletter.org/TML-article-1205d | Show Introduction Hide Introduction
Topical Pimecrolimus (Elidel) for treatment of atopic dermatitis
The Medical Letter on Drugs and Therapeutics • May 27, 2002 (Issue 1131)
Pimecrolimus 1% cream (pim e kroe' limus; SDZ ASM 981; Elidel - Novartis) has been approved by the FDA for short-term and intermittent long-term treatment of mild to moderate atopic dermatitis in non-immunocompromised patients at least 2 years old.
http://secure.medicalletter.org/TML-article-1131b | Show Introduction Hide Introduction
Topical Tacrolimus For Treatment of Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Apr 16, 2001 (Issue 1102)
Tacrolimus ointment (Protopic) has been approved by the FDA in 0.03% and 0.1% formulations for treatment of atopic dermatitis. Tacrolimus is used systemically (Prograf) to prevent rejection of organ transplants.
http://secure.medicalletter.org/TML-article-1102b | Show Introduction Hide Introduction
